Supplementary Figure 2 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Q: What type of study is this?

This is a Targeted Sequencing study (also classified as: Whole-Genome Sequencing).

Gillian Vandekerkhove; Andrew J. Murtha; David C. Müller; Maria Stephenson; Kimia Rostin; Aslı D. Munzur; Carlos Vasquez-Rios; Jussi Nikkola; Joonatan Sipola; Matti Annala; Cameron Herberts; Emily Fung; Jaskirat Atwal; Sadeem Al-Subaie; Karan Parekh; Cecily Q. Bernales; Gráinne Donnellan; Daygen L. Finch; Krista Noonan; Jenny J. Ko; Güliz Özgün; Lucia Nappi; Christian Kollmannsberger; Jean‐Michel Lavoie; Sunil Parimi; Tilman Todenhöfer; Piet Ost; Gang Wang; Peter C. Black; Corinne Maurice‐Dror; Kim N.; Bernhard J. Eigl; Alexander W. Wyatt

doi:10.1158/1078-0432.30029657

Key Points

Genomic alterations were revealed in circulating tumor DNA, highlighting changes during disease progression.
Targeted sequencing identified significant mutations in ERBB2/HER2 in patients with metastatic urothelial cancer.
Whole-genome sequencing provided comprehensive insights into both ctDNA and metachronous tissues' genomic profiles.
The study emphasizes the potential for ctDNA testing in monitoring tumor evolution and treatment response.

Implication

Analysis detects genomic alterations via targeted sequencing and whole-genome sequencing in metastatic urothelial cancer, suggesting insights into tumor evolution.

Abstract

Supplementary Figure 2. Targeted and whole-genome sequencing (WGS) of metastatic urothelial cancer (mUC) circulating tumor DNA (ctDNA).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vandekerkhove et al. (2025) studied this question.

synapsesocial.com/papers/68bb5f076d6d5674bcd02b30 https://doi.org/10.1158/1078-0432.30029657

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure 2 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 2 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading